Cerapedics entered into a supplier agreement with Vizient, a U.S. provider-driven healthcare performance improvement company, for PearlMatrix P-15 Peptide Enhanced Bone Graft, a Class III drug/device combination product for adult patients with degenerative disc disease in the lumbar spine.
This agreement will offer enhanced access to the first bone growth accelerator designed to accelerate lumbar fusion, along with enhanced savings for PearlMatrix to Vizient clients, including academic medical centers, community hospitals, and integrated health delivery networks.
With the addition of PearlMatrix, Vizient clients have increased access to the Cerapedics portfolio of peptide-powered drug-device products with demonstrated clinical performance for spinal fusion, which also includes i-FACTOR for single-level anterior cervical discectomy and fusion. Vizient serves more than 65% of the nation’s acute care providers, including 97% of academic medical centers and 35% of the non-acute market.
Cerapedics entered into a supplier agreement with Vizient, a U.S. provider-driven healthcare performance improvement company, for PearlMatrix P-15 Peptide Enhanced Bone Graft, a Class III drug/device combination product for adult patients with degenerative disc disease in the lumbar spine.
This agreement will offer enhanced access to the first...
Cerapedics entered into a supplier agreement with Vizient, a U.S. provider-driven healthcare performance improvement company, for PearlMatrix P-15 Peptide Enhanced Bone Graft, a Class III drug/device combination product for adult patients with degenerative disc disease in the lumbar spine.
This agreement will offer enhanced access to the first bone growth accelerator designed to accelerate lumbar fusion, along with enhanced savings for PearlMatrix to Vizient clients, including academic medical centers, community hospitals, and integrated health delivery networks.
With the addition of PearlMatrix, Vizient clients have increased access to the Cerapedics portfolio of peptide-powered drug-device products with demonstrated clinical performance for spinal fusion, which also includes i-FACTOR for single-level anterior cervical discectomy and fusion. Vizient serves more than 65% of the nation’s acute care providers, including 97% of academic medical centers and 35% of the non-acute market.
Copy to clipboard 
